Trial Profile
A Phase I/II Multi Centre Single Arm, Open Label Study of Intraparenchymal Therapy With Irinotecan Hydrochloride Drug-eluting Beads (CM-BC2) as a Adjunct Therapy to Best Standard of Care in Patients With Recurrent, Surgically Resectable High Grade Glioma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Apr 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms IDEB-glioma
- Sponsors BTG International
- 15 Dec 2020 Status changed from active, no longer recruiting to discontinued.
- 08 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Jun 2015 New trial record